| Metric | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.54B | $10.60B | $42.88B | $10.36B | $10.86B | $11.12B | $44.56B | $11.01B |
| Net Income | $1.55B | $1.63B | $6.33B | $1.51B | $1.62B | $1.62B | $6.70B | $1.65B |
| EPS (Diluted) | $4.04 | $4.25 | $16.53 | $3.98 | $4.28 | $4.27 | $17.74 | $4.43 |
Consensus Recommendation
Strong BuyBased on 25 analyst opinions
| Target High | $750.00 |
| Target Mean | $611.56 |
| Target Low | $490.00 |
| Current Price | $442.00 |
| Upside Potential | +38.4% |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as ...
| Sector | Healthcare |
| Industry | Life Sciences |
| Employees | 125,000 |
| Headquarters | Waltham, MA, United States |
| Website | https://www.thermofisher.com |
| Exchange | NYQ |
| Currency | USD |
| Shares Outstanding | 371.62M |
| Insider Ownership | 0.2% |
| Institutional Ownership | 94.2% |
| EPS (TTM) | 18.21 |
| EPS (Forward) | 27.30 |
| PEG Ratio | 1.45 |
| Next Earnings Date | 2026-04-23 |
🔗 More on emfls.github.io
Reviewed on August 11, 2026. Information, tool output, prices, rules, and service conditions can change or vary by device and input. Verify primary and current official sources before important use.